Page 1

BUSINESS HIGHLIGHTS THIRD-QUARTER 2025 RESULTS TOTAL COMPANY *Organic sales growth excludes impact of foreign exchange and the impact of discontinuing the ZonePerfect ® product line in the Nutrition business. For full financial data and reconciliation of non-GAAP measures, please see our press release dated Oct. 15, 2025, available at www.abbottinvestor.com. **Excludes the impact of COVID-19 testing sales. 1. On a GAAP basis, third-quarter Abbott sales increased 6.9%. 2. Third-quarter 2025 GAAP diluted EPS was $0.94. 3. Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition related expenses, and foreign exchange, which could significantly impact Abbott’s results in accordance with GAAP. FORWARD-LOOKING STATEMENTS Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended Dec. 31, 2024, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. ADJUSTED DILUTED EPS $1.30 2 SALES WORLDWIDE $11.4B +7.5% 1 Organic* sales growth for underlying base business** $2.3B DIAGNOSTICS $5.4B MEDICAL DEVICES $1.5B ESTABLISHED PHARMACEUTICALS $2.2B NUTRITION KEY BUSINESS UNITS EXPANDING ALTERNATIVES TO OPEN-HEART SURGERY CE Mark for an expanded indication for our Navitor® transcatheter aortic valve implantation system. Approved to treat people with symptomatic, severe aortic stenosis who are at low or intermediate risk for open-heart surgery. EXTENDING GLOBAL REACH OF STRUCTURAL HEART INNOVATION Regulatory approval in Japan for TriClip®. Device is a first-of-its-kind, minimally invasive treatment option for patients with a leaky tricuspid heart valve. Abbott, which screens more than 50% of the world’s blood supply, teamed up with the Big Ten Conference to rally students, alumni and fans in a nationwide blood donation competition. Blood is needed every two seconds in the U.S. — and some centers have less than a day’s supply. TACKLING THE BLOOD SUPPLY SHORTAGE ADJUSTED DILUTED EPS $5.12 to $5.18 3 7.5% to 8.0% 3 Excluding COVID-19 testing-related sales Narrowed range reflects double-digit growth at the midpoint REAFFIRMED FULL-YEAR GUIDANCE ORGANIC SALES GROWTH